Yes, tuberculosis can affect the liver in two distinct ways: the TB bacteria themselves can infect liver tissue directly, and the medications used to treat TB can cause liver damage as a side effect. Direct liver involvement is surprisingly common, found in 75% to 100% of patients with miliary (widespread) TB and roughly 20% of patients with pulmonary TB alone. Drug-related liver injury occurs in 5% to 28% of people on standard TB treatment.
How TB Bacteria Reach the Liver
TB bacteria travel to the liver through the bloodstream, arriving via the portal vein or the hepatic artery. Once there, they can cause different patterns of disease. The most common form is miliary hepatic TB, where tiny clusters of infected tissue called tubercles scatter throughout the liver as part of a widespread infection. This form has been found in 50% to 80% of all patients who die from pulmonary TB, though many of those cases were never diagnosed during life because the liver involvement produced no obvious symptoms.
Less commonly, TB can cause a localized infection in the liver, forming larger nodules called tuberculomas. These range from 1 to 4 cm in diameter and often contain small calcium deposits. TB can also affect the bile ducts running through the liver, causing strictures that block bile flow and lead to painless jaundice and weight loss. This presentation is particularly tricky because it closely mimics bile duct cancer or pancreatic cancer on imaging.
Symptoms of Liver TB
Hepatic TB is often silent, which is part of what makes it difficult to catch. When symptoms do appear, the most common is an enlarged liver, found in about 80% of diagnosed cases. Fever occurs in roughly two-thirds of patients, followed by abdominal pain (about 60%), weight loss (about 58%), and respiratory symptoms from coexisting lung TB (about 66%).
Other findings include an enlarged spleen (around 30% of cases), fluid buildup in the abdomen (about 23%), and yellowing of the skin and eyes (about 20%). Right upper quadrant pain or vague abdominal discomfort is present in 65% to 87% of patients across multiple case series. Because these symptoms overlap with so many other conditions, from hepatitis to liver cancer, liver TB is frequently misdiagnosed or discovered late.
How Liver TB Is Diagnosed
Liver TB has no signature appearance on imaging. Ultrasound and CT scans may show low-density lesions or calcified spots, but these look similar to tumors or metastatic cancer. The most consistent imaging clue is calcified or low-density nodules with bile duct widening, particularly when active lung disease is also present. Still, without a high degree of suspicion, the diagnosis is often missed.
Blood tests provide supporting evidence. The liver enzymes alkaline phosphatase (ALP) and GGT tend to rise significantly, while the standard liver inflammation markers (ALT and AST) may stay only mildly elevated. A characteristic pattern is an inverted albumin-to-globulin ratio, where globulin levels run 1.25 to 1.86 times higher than albumin. This combination of findings, elevated ALP and GGT with a flipped protein ratio, should raise suspicion for liver TB in areas where the disease is common.
Liver biopsy remains the gold standard. Under the microscope, the hallmark is clusters of immune cells called granulomas, often with distinctive giant cells. A special stain for TB bacteria is positive in only about 40% of cases, so a genetic test (PCR) with 82% sensitivity is often used to confirm the diagnosis when the stain comes back negative.
Liver Damage From TB Medications
Even when TB hasn’t directly infected the liver, treatment itself poses a risk. The standard combination of TB drugs is one of the most common causes of drug-induced liver injury worldwide, reported in 5% to 28% of treated patients. It is the single most frequent side effect that forces doctors to stop or change TB medications, affecting about 11% of patients on the standard three-drug regimen.
The damage isn’t caused by the drugs directly. Instead, the liver breaks these medications down into toxic byproducts that can bind to and injure liver cells. Two key enzymes in the liver control how quickly these byproducts form and accumulate, which partly explains why some people tolerate the drugs well while others develop problems. Genetic variation in these enzymes plays a role in individual susceptibility.
Monitoring Your Liver During Treatment
Before starting TB treatment, baseline blood work including liver enzymes, bilirubin, and a platelet count is recommended for all adults. For people with pre-existing liver conditions like hepatitis B or C, cirrhosis, or HIV, liver function tests are recommended weekly for the first month, then every two weeks for two more months, then monthly for the rest of treatment.
The key warning signs that liver toxicity has become serious enough to pause treatment are straightforward. If liver enzymes rise above five times the normal upper limit, even without symptoms, medications are stopped. If enzymes reach three times normal and you also develop jaundice or symptoms like nausea, fatigue, or abdominal pain, treatment is also paused. Mild toxicity is classified as enzyme levels under five times normal, moderate is five to ten times, and severe is anything above ten times normal.
For people who already had abnormal liver function before starting treatment, these thresholds don’t apply cleanly. In those cases, a jump of 50 to 100 units above baseline levels may be the more appropriate trigger for concern, since the standard “five times normal” cutoff could be dangerously high for someone starting from an already elevated baseline.
People at Higher Risk for Liver Problems
Anyone with pre-existing liver disease faces a more complicated treatment course. People with chronic hepatitis B or C, alcoholic liver disease, or cirrhosis need closer monitoring and may need modified drug regimens that use fewer liver-toxic medications. HIV-positive patients on antiretroviral therapy also face higher risk because both their HIV drugs and TB drugs are processed through the liver. Pregnant women and those in the first three months after giving birth are also flagged for more intensive monitoring.
Interestingly, some risk factors that seem intuitive haven’t held up in studies. At least one controlled trial found no significant link between age, sex, alcohol intake, or body weight and the likelihood of developing drug-induced liver injury during TB treatment. However, among those who did develop liver problems, older patients (average age 47) were more likely to experience fatal complications than younger ones (average age 39).